Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
11,749
datasets available to search
ShareScore release 0.9.0
Dataset results
11,749 results for “patient safety”
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
ClinicalTrials.gov study NCT01151423. IPD Sharing: YES. Countries: 13. Publications: 3.
Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis
ClinicalTrials.gov study NCT02896127. IPD Sharing: UNDECIDED. Countries: 4. Publications: 3.
In-hospital patient safety events, healthcare costs and utilization: an analysis of data from the incident reporting system in an academic medical center
<p>Raw Datasets for the study 'In-hospital patient safety events, healthcare costs and utilization: an analysis of data from the incident reporting system in an academic medical center'.</p>
A scoping review of patient safety research carried out in the Republic of Ireland [dataset]
<p>This is an example search strategy (supplemental materials 1) and the charting form data (supplemental materials 2) from each of the 31 included papers included in the scoping research.</p> <p><strong>Background.</strong> Maintaining the highest levels of patient safety is a priority of healthcare organisations. However, although considerable resources are invested in improving safety, patients still suffer avoidable harm.</p> <p><strong>Aims.</strong> (1) To examine the extent, range, and nature of patient safety research activities carried out in the RoI; (2) make recommendations for future research; and (3) consider how these recommendations align with the Health Service Executive’s (HSE) patient safety strategy.</p> <p><strong>Methods.</strong> A five-stage scoping review methodology was used to synthesise the published research literature on patient safety carried out in the RoI: (1) identify the research question; (2) identify relevant studies; (3) study selection; (4) chart the data; and (5) collate, summarising, and reporting the results. Electronic searches were conducted across five electronic databases.</p> <p><strong>Results.</strong> A total of 31 papers met the inclusion criteria. Of the 24 papers concerned with measuring and monitoring safety, 12 (50%) assessed past harm, 4 (16.7%) the reliability of safety systems, 4 (16.7%) sensitivity to operations, 9 (37.5%) anticipation and preparedness, and 2 (8.3%) integration and learning. Of the six intervention papers, three (50%) were concerned with education and training, two (33.3%) with simplification and standardisation, and one (16.7%) with checklists. One paper was concerned with identifying potential safety interventions.</p> <p><strong>Conclusions.</strong> There is a modest, but growing, body of patient safety research conducted in the RoI. It is hoped that this review will provide direction to researchers, healthcare practitioners, and health service managers, in how to build upon existing research in order to improve patient safety.</p>
Factors related to the implementation of patient safety culture in prehospital emergency services
<p><span>Background</span><span>: Prehospital emergency services are one of the main areas of health care, which provide emergency services for patients who experience acute, critical illness or injury outside the hospital. Prehospital services are more often carried out by the Emergency Medical Services (EMS) team, as one of the health service providers who come to the scene more quickly, both in daily emergencies.</span></p> <p><span>Purpose</span><span>: </span><span>This study aims to determine the factors related to the application of patient safety culture and determine the most dominant factors in the application of patient safety culture at </span><span>the prehospital emergency service in Bantaeng.</span></p> <p><span>Results:</span><span> The results showed that all domains of patient safety culture had a significant effect (p<0.05) namely teamwork 0.000, safety climate 0.000, management perception and support 0.000, job satisfaction 0.019, work environment 0.000 and stress recognition 0.000. The most influential domain is stress recognition 1.116 and Adjust R Square value of 69.7%.</span></p> <p><span>Conclusion:</span><span> Patient safety needs to be a priority in handling and organizations must continue to evaluate the application of patient safety culture in PSC 119 setting in Bantaeng. Nurses are responsible for improving services that prioritize patient safety by understanding all factors related to the implementation of patient safety culture.</span></p>
Gastric Residual Volume, Safety and Effectiveness of Drinking 250ml Glucose Solution 2-3 Hours before Surgery in Gastric Cancer Patients: A Multicenter, Single-blind, Randomized Controlled Trial
<p><strong>Supplementary Figure 1</strong></p> <p> </p> <p>A. Change of QUICKI level after surgery</p> <p>Post-OP: right after operation; POD: post-operation day; Mixed linear model statistics showed that the effect of time ( p=0.004) was significant, but no significant differences were noted for group(P=0.600) or group*time(P=0.963).</p> <p>B. Change of Recovery Level of QUICKI after surgery</p> <p>Post-OP: right after operation; POD: post-operation day; Mixed linear model statistics showed that no significant differences were noted for group(P=0.600) ,time (P=0.235) or group×time(P=0.963).</p> <p>C. Change of WBC level after surgery</p> <p>Post-OP: right after operation; POD: post-operation day; Mixed linear model statistics showed that the effect of time ( p<0.001) was significant, and no significant differences were noted for group(P=0.392) or group×time(P=0.314).</p> <p>D. Change of CRP level after surgery</p> <p>Post-OP: right after operation; POD: post-operation day; Mixed linear model statistics showed that the effect of time ( p<0.001) was significant, but no significant differences were noted for group(P=0.312) or group × time(P=0.826).</p>
Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis
<p>This dataset was the minimal dataset of the research article entitle 'Safety of ChAdOx1 nCoV-19 vaccination in patients with end-stage renal disease on hemodialysis'. The study aims to investigate the localized and systemic adverse effects (AEs) within 30-days after the first dose of ChAdOx1 nCoV19 (Oxford-AstraZeneca) vaccination in end-stage renal disease (ESRD) patients receiving hemodialysis (HD). The first dataset is the raw data for logistic regression analyses examining the risk factors in association with AEs, another dataset contains the second- and the seventh- day incidences of various AEs depicted in bar graphs. It comprises variables recording the status of patient-reported local and systemic AEs in questionnaire on the second and seventh days after vaccination as well as patients' baseline demographic and clinical characteristics.</p>
Assessment of Patient Safety Culture and Associated Factors among Healthcare Professionals in Public Hospitals of Bahir Dar City, Northwest Ethiopia: A Mixed-Methods Study
<p>This data set contains HSOPSC on the <span>Assessment of Patient Safety Culture and Associated Factors among Healthcare Professionals in Public Hospitals of Bahir Dar City, Northwest Ethiopia: A Mixed-Methods Study</span></p>
Assessment of Patient Safety Culture and Associated Factors among Healthcare Professionals in Public Hospitals of Bahir Dar City, Northwest Ethiopia: A Mixed-Methods Study
<p><span>This dataset contains raw data on "regression analyses" on the assessment of patient safety culture among healthcare professionals in public hospitals of Bahir Dar City, Northwest Ethiopia."</span></p>
Assessment of Patient Safety Culture and Associated Factors among Healthcare Professionals in Public Hospitals of Bahir Dar City, Northwest Ethiopia: A Mixed-Methods Study
<p><span>This dataset contains raw data of " </span><span>Likert Scale Descriptive Analysis"on t</span><span>he assessment of patient safety culture among healthcare professionals in public hospitals of Bahir Dar City, Northwest Ethiopia.</span></p>
Raw Data for the article: COVID-19 safety measures at the Radiology Unit of a Transplant Institute: the non-COVID-19 patient's confidence with safety procedures
<p><strong>Purpose: </strong>To support the wellbeing of both patients and their families, our aim was to investigate the satisfaction of non-COVID in- and out-patients regarding safety measures implemented at our radiology unit of a transplant institute against COVID infection.</p> <p><strong>Materials and methods: </strong>Over a five-month period, adult patients' feedback was obtained by a questionnaire on the fear of contracting COVID-19 during a radiology examination, the perceived delay in treatment, and the following safety measures implemented: modified schedules to limit the number of patients in the waiting area and to maximize social distancing; assistance by staff when visitors were not admitted; cleaning and disinfection of machines; mask wearing and hand hygiene of staff; and staff advice on hand hygiene and infection control precautions.</p> <p><strong>Results: </strong>Over a five-month period, our preliminary results (387 patients) showed general patient satisfaction (99.1%) with safety measures applied at our radiology unit. Patients were satisfied with distancing and assistance by staff (100%), cleaning and disinfection (91%), mask wearing and hand hygiene of the staff (97%), and staff advice (94%). There was some criticism of the perceived delay in treatment (7.3%) and in the scheduling of the waiting list (5.4%), with 5.4% fearing contracting the virus. Patients' awareness of safety measures and confidence in the hospital preparedness policy was perceived by all interviewers, and 100% appreciated being questioned.</p> <p><strong>Conclusion: </strong>The feedback given by the non-COVID patient helps to measure the quality in health care, to improve the quality service, and to protect and satisfy more vulnerable patients, also during the COVID-19 pandemic.</p>
The effectiveness and safety of intensive lipid-lowering with different Rosuvastatin-based regimens in patients at high risk: A nonblind, randomized, controlled trial
<p><span><strong>Background</strong>:</span> <span>Statin alone or nonstatins as add-ons have been introduced to intensive low-density lipoprotein cholesterol (LDL-C) </span><span>lowering</span><span> therapy in patients at high cardiovascular disease (CVD) risk. The purpose of this study was to evaluate the effectiveness and safety of different statin-based regimens for patients at high risk</span><span>.</span></p> <p><span><strong>Methods</strong>:</span> <span>Three hundred patients at high CVD risk were randomly assigned to the statin group</span><span> (Rosuvastatin 20mg/d</span><span>), statin_EZ group</span> <span>(Rosuvastatin 10mg/d + ezetimibe </span><span>10mg/d</span><span>), statin_pcsk group (Rosuvastatin </span><span>10mg/d</span><span> + alirocumab </span><span>75mg/2</span><span>weeks) or combine3 group (Rosuvastatin 10mg/d + ezetimibe 10mg/d + alirocumab 75mg/2weeks)</span><span>.</span> <span>The primary outcome measure was cholesterol levels </span><span>(LDL-C, total cholesterol (TC) triglycerides (TGs), and high-density lipoprotein cholesterol (HDL-C))</span><span> after 24</span><span> weeks of</span><span> follow-up. The secondary outcome measures were safety markers and the proportion of patients who achieved the < 70 mg/dL (1.8 mmol/L) LDL-C target. </span><span>A logistic</span><span> regression model was performed to explore the factors affecting lipid target achievement.</span></p> <p><span><strong>Results</strong>:</span> <span>The TC and LDL-C levels after treatment were significantly different among the four groups</span> <span>(p < 0.05). The levels in both the combine3 group and </span><span>the </span><span>statin_pcsk9 group were significantly lower than </span><span>those in </span><span>the statin group and the statin_EZ group (</span><span>p < 0.05</span><span>), but there was no significant difference between</span><span> the</span><span> combine3 group and </span><span>the </span><span>statin_pcsk9 group. The incidence of adverse events in the four groups was low.</span><span> Body mass index (BMI) and hypertensive status were related to target achievement.</span></p> <p><span><strong>Conclusion</strong>:</span><span> The combination of a statin</span><span> and a PCSK9 inhibitor was safe and more effective for the treatment of high-risk CVD patients, while the addition of </span><span>ezetimibe was</span><span> unable to significantly lower lipid levels any further. The rate of achieving </span><span>the </span><span>target was higher in patients </span><span>with</span><span> hypertension and a low BMI.</span></p>
The efficacy and safety of meal replacement in patients with type 2 diabetes: a systematic review and meta-analysis
<p>There are supplemental materials for a systematic review and meta-analysis, which studied the efficacy and safety of meal replacement in patients with type 2 diabetes, with a focus on subgroup analysis of variable participant characteristics and MR prescription.</p>
Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML
ClinicalTrials.gov study NCT03727750. IPD Sharing: YES. Countries: 6. Publications: 1.
A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
ClinicalTrials.gov study NCT03188666. IPD Sharing: Not stated. Countries: 8. Publications: 4.
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
ClinicalTrials.gov study NCT01781429. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
ClinicalTrials.gov study NCT02118012. IPD Sharing: Not stated. Countries: 1. Publications: 1.
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
ClinicalTrials.gov study NCT00791492. IPD Sharing: Not stated. Countries: 6. Publications: 5.
The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour.
ClinicalTrials.gov study NCT02430311. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Safety and Efficacy of Repeat Administration of Ad/PNP and Fludarabine Phosphate in Patients With Local Head/Neck Cancer
ClinicalTrials.gov study NCT03754933. IPD Sharing: NO. Countries: 1. Publications: 2.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.